Onsior is a non-steroidal anti-inflammatory drug-Hyperdrug

Presentation Round, beige to brown non-divisible tablets with imprints "NA" on one side and "AK" on the other side. Each tablet contains 6 mg robenacoxib as active ingredient. The tablets are palatable (yeast flavoured), easy to administer and well accepted by most cats. Uses Onsior is a non-steroidal anti-inflammatory drug (NSAID) for use in cats. Robenacoxib is part of the coxib class of NSAIDs and is recommended for the treatment of acute pain and inflammation associated with musculoskeletal disorders in cats. Robenacoxib is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2). The cyclooxygenase enzyme (COX) is present in 2 forms. COX-1 is the constitutive form of the enzyme and has protective functions, e.g. in the gastrointestinal tract and kidneys. COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including prostaglandin E2 (PGE2) which induce pain, inflammation or fever. In the in vitro whole blood assay in cats, robenacoxib was approximately 500 fold selective for COX-2 as compared to COX-1. 1-2 mg/kg robenacoxib tablets produced a marked inhibition of COX-2 activity in cats and had no effect on COX-1 activity. After oral administration of robenacoxib tablets at approximately 2 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h. Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h). Robenacoxib is highly bound to plasma proteins (>99%) and extensively metabolised by the liver in cats. It is rapidly cleared from blood. After oral administration of tablets, the terminal half-life from blood was 1.7h. Robenacoxib persists longer and at higher concentrations at sites of inflammation that in blood. Robenacoxib is excreted predominantly via the biliary route (~70%) rather than via the kidneys (~30%).

Contra-indications, warnings, etc Do not use in cats suffering from gastrointestinal ulceration. Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of hypersensitivity to the active substance or to any of the excipients. Because the safety of robenacoxib has not been established during pregnancy and lactation or in cats used for breeding it is therefore not recommended for use in pregnant and lactating animals. The safety of the veterinary medicinal product has not been established in cats weighing less than 2.5 kg or under 4 months of age. Use in cats with impaired cardiac, renal or hepatic function or in cats that are dehydrated, hypovolaemic or hypotensive may involve additional risks. If use cannot be avoided, these cats require careful monitoring. Use this veterinary medicinal product under strict veterinary monitoring in cats with a risk of gastrointestinal ulcers, or if the cat previously displayed intolerance to other NSAIDs. Mild and transient diarrhoea, soft faeces or vomiting were commonly reported. Onsior must not be administered in conjunction with other NSAIDs. Pre-treatment with other anti-inflammatory medicines may result in additional or increased adverse effects and, accordingly a treatment-free period with such substances should be observed for at least 24 hours before the commencement of treatment with Onsior. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. Concomitant treatment with medicines displaying action on renal flow, e.g. diuretics or angiotensin converting enzyme (ACE) inhibitors, should be subject to clinical monitoring. Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity. Concurrent use of other active substances that have a high degree of protein binding may compete with robenacoxib for binding and thus lead to toxic effects. Pharmaceutical precautions Store below 30°C. Wash hands after use of the veterinary medicinal product. In small children, accidental ingestion increases the risk for NSAID adverse effects. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. For pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk for premature closure of the ductus arteriosus in the foetus.

Legal category POM-V Packaging Quantities Cardboard box containing 1, 2, 5 or 10 Alu/Alu blisters. Each blister contains 6 tablets. Any unused medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Further information In healthy young cats aged 7-8 months, oral robenacoxib administered at high overdoses (4, 12, or 20 mg/kg/day for 6 weeks) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time. As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised cats. There is no specific antidote. Symptomatic, supportive therapy is recommended and should consist of administration of gastrointestinal protective agents and infusion of isotonic saline.

Onsior 6mg Flavoured Tablets for cats (pack of 30)